Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Phase II Clinical Study to Evaluate the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs KL 7016 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors KT&G Life Sciences
- 08 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Mar 2014 New trial record